Chicago– Tempus AI, Inc. (NASDAQ: TEM), a leading technology firm harnessing artificial intelligence to advance precision medicine, has announced the formation of a new advisory board composed of prominent physicians from across the United States.
The Tempus Advisory Board is designed to provide strategic guidance, clinical insight, and expert feedback on the company’s AI-powered platform, with a focus on research, product development, and real-world clinical utility.
“From day one, we’ve believed that clinical needs and robust science should drive our efforts,” said Dr. Ezra Cohen, Chief Medical Officer for Oncology at Tempus. “This board reflects that commitment. We’re excited to collaborate with such a distinguished group of medical leaders as we continue to grow and evolve.”
The newly established board includes specialists from major academic and clinical institutions, covering a wide range of expertise in oncology and precision medicine. Among the members are:
-
Dr. David Carbone, Director of the James Thoracic Oncology Center at Ohio State University Medical Center.
-
Dr. Babar Bashir, Associate Professor at Thomas Jefferson University, with dual appointments in oncology and cancer biology.
-
Dr. Amy Cummings, Assistant Professor in hematology/oncology at UCLA.
-
Dr. Tapan Kadia, Professor in the Department of Leukemia at MD Anderson Cancer Center.
-
Dr. Marc Matrana, System Director of Precision Medicine at Ochsner MD Anderson and Professor at the University of Queensland.
-
Dr. Robert McWilliams, Consultant and Professor of Oncology at the Mayo Clinic, also serving as Deputy Director at its Comprehensive Cancer Center.
-
Dr. Tara Mitchell, Section Chief of Melanoma and Sarcoma at the University of Pennsylvania.
-
Dr. Nicholas Mitsiades, Professor of Medicine and Associate Director for Translational Research at UC Davis Comprehensive Cancer Center.
-
Dr. Ben Park, Director of the Vanderbilt-Ingram Cancer Center and Professor of Medicine.
-
Dr. B.J. Rimel, Medical Director of the Cancer Clinical Trials Office at Cedars-Sinai Cancer.
-
Dr. Mothaffar Rimawi, Executive Medical Director of the Dan L Duncan Comprehensive Cancer Center.
-
Dr. Assuntina Sacco, Professor at UC San Diego Health and Co-Director of the Head and Neck Center of Excellence.
-
Dr. Alexander Spira, Director of NEXT Oncology Virginia and Co-Director of the Virginia Cancer Specialists Research Institute.
The board is expected to play a key role in helping Tempus ensure that its technology and offerings remain closely aligned with clinical practice and emerging medical needs.
